# Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

> **NCT03410615** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Canadian Cancer Trials Group** · enrollment: 129 (actual)

## Conditions studied

- Oropharyngeal Squamous Cell Carcinoma

## Interventions

- **RADIATION:** Radiation
- **DRUG:** Cisplatin
- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT03410615
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-05-28
- **Primary completion:** 2026-01-09
- **Final completion:** 2026-07-31
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03410615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03410615, "Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03410615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*